Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma

doi:10.4251/wjgo.v17.i1.96267

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (670)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

HTML

256

Figures (1-2)

Tables (1-3)

Sum=391

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

100

Sum=175

Publishing Process of This Article

Item

Count

Browse

Download

Sum=78

Jan 15, 2025 (publication date) through Jan 10, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Jan 15, 2025; 17(1): 96267
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.96267

Table 2 Tumor response at 1 year based on modified response evaluation criteria in solid tumors, n (%)

	Unmatched group		Matched group
	TACE + L (n = 27)	TACE + SL (n = 30)	TACE + L (n = 15)	TACE + SL (n = 15)
CR	4 (14.8)	6 (20.0)	1 (6.7)	2 (13.3)
PR	11 (40.7)	15 (50.0)	7 (46.7)	9 (60.0)
SD	2 (7.4)	6 (20.0)	1 (6.7)	3 (20.0)
PD	10 (37.0)	3 (10.0)	6 (40.0)	1 (6.7)
ORR	15 (55.6)	21 (70.0)	8 (53.3)	11 (73.3)
DCR	17 (63.0)	27 (90.0)	9 (60.0)	14 (93.3)
1-year OS	19 (70.4)	26 (86.7)	12 (80)	14 (93.3)

TACE + L: Transarterial chemoembolization with lenvatinib alone; TACE + SL: Transarterial chemoembolization combined with lenvatinib and sintilimab; CR: Complete response; PR: Partial response; SD: Stable response; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate; OS: Overall survival.

Citation: Wu FD, Zhou HF, Yang W, Zhu D, Wu BF, Shi HB, Liu S, Zhou WZ. Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(1): 96267
URL: https://www.wjgnet.com/1948-5204/full/v17/i1/96267.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i1.96267